Hangzhou Hengyan Biopharmaceutical Co., Ltd.
Focused on the R&D of AI-programmable multivalent protein therapeutics
Hangzhou Hengyan Biopharmaceutical Co., Ltd. is an innovative joint-venture pharmaceutical company co-founded by Youlike (Hangzhou) Biotech Co., Ltd. and Westlake University, focusing on the R&D of AI-programmable multivalent protein therapeutics.
Centered on the ZT modular scaffold platform featuring exceptional stability and unique structures, the company integrates AI protein structure prediction and molecular simulation technologies to carry out rational design of peptides and proteins, developing a new generation of programmable, multi-target and multivalent protein therapeutics. Its core R&D directions are as follows:
1. Design and optimization of multimeric fusion proteins: Using the ZT trimer scaffold as the carrier for site-specific fusion of peptides or protein domains. AI simulation is applied to evaluate conformational stability, and linker sequences are rationally optimized to improve the biological activity and structural stability of molecules.
2. Screening of multiple insertion sites and linker engineering: The ZT scaffold has multiple modifiable sites for simultaneous loading of multiple functional modules. AI is used to screen optimal fusion sites and engineer linkers to reduce steric hindrance, thereby improving molecular activity and druggability.
3. Directed engineering of peptides and proteins: AI models are adopted to redesign sequences and introduce site-directed mutagenesis for peptides and target proteins to enhance target binding affinity. Physicochemical properties are optimized concurrently to improve protein solubility and anti-aggregation performance.
4. Rational optimization of fusion protein immunogenicity: AI models scan the full-length protein to identify potential epitopes. Amino acid modifications are performed without disrupting protein folding and biological activity to reduce immunogenic risk and improve molecular safety.
Leveraging the strengths of industry-university-research collaboration, the company has built a complete R&D closed loop ranging from AI molecular design to protein engineering optimization. It develops differentiated innovative multi-target fusion protein therapeutics with independent intellectual property rights, committed to addressing unmet clinical needs.